Opinion|Videos|August 6, 2026
Bringing it All Together: Final Thoughts
Finally, Zepcan and Ali reflect on the single most important lessons for pharmacists new to menin inhibitor therapy and share what they wish they'd known on day one.
Advertisement
Episodes in this series
Finally, Zepcan and Ali reflect on the single most important lessons for pharmacists new to menin inhibitor therapy and share what they wish they'd known on day one. They discuss what needs to change in current practice and offer actionable first steps pharmacists can take tomorrow to optimize their approach to therapy selection, monitoring, and patient counseling in this emerging drug class.
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
The all-oral combination is supported by phase 3 LITESPARK-011 data showing improved progression-free survival compared with cabozantinib.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5